Digital therapeutics company Pear Therapeutics is looking to integrate digital biomarkers, machine learning algorithms, and sensor-based technologies into its DTx platform thanks to new licensing deals and partnerships.
Specifically, Pear’s collaboration with Empatica will focus on the use of medical-grade wearables and digital biomarkers. The company is looking to use wearables to evaluate a patient’s withdrawal symptoms from opioids, alcohol and other substances.
The etectRx partnership will focus on medication adherence. Pear will now be able to integrate etectRx’s digital pill, which can show if a patient ingested the medication. This partnership isn’t a surprise. In January, the two companies announced a deal to potentially develop a product that combines the former’s DTx with a digital pill offering. At the time, the companies’ plan was to meet quarterly to discuss that potential.Read more about DTx Company Pear Inks Slew of Deals To Integrate More Digital Biomarkers and a Digital Pill Into Platform.